Tomohisa Saito
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis.
Journal: British journal of clinical pharmacology
Published: February 07, 2025
Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis.
Journal: Journal of drugs in dermatology : JDD
Published: October 06, 2023
Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis.
Journal: Drug research
Published: September 06, 2021
Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?
Journal: Clinical pharmacology in drug development
Published: August 18, 2021
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: March 20, 2020
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Journal: Japanese journal of clinical oncology
Published: February 18, 2020
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Journal: Drug research
Published: August 14, 2018
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation.
Journal: Journal of clinical pharmacology
Published: March 05, 2017
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.
Journal: Clinical pharmacokinetics
Published: December 31, 2015
Last Updated: 09/26/2026